Skip to main content

Qiagen Value Stock - Dividend - Research Selection

Qiagen

ISIN: NL0012169213 , WKN: A2DKCH

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions. It also provides Ingenuity Variant Analysis, a cloud-based platform that interprets data from next-generation sequencing (NGS) analysis; QIAGEN Clinical Insight, an evidence-based decision support solution; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web-based portal that enables researchers to search and select gene-and pathway-specific solutions from pre-designed and custom PCR assay kits, NGS assay panels, and other products. In addition, the company offers instrumentation systems for laboratories. Its automation platforms include QIAsymphony, a modular system; GeneReader NGS System, a sample to insight NGS solution for laboratories to deliver actionable results; QIAcube robotic workstations, which provides versatile solutions for automated sample processing; QIAxcel for nucleic acid separation; QIAgility, a benchtop instrument for PCR setup; and ESEQuant instruments that enable optical measurement for point of need molecular testing in physician practices, emergency rooms, remote areas, and other applications. It serves molecular diagnostics, applied testing, pharma, and academia customers. QIAGEN N.V. has a collaboration with Bristol-Myers Squibb to develop gene expression profiles for immuno-oncology therapies. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


QIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026

2026-04-16
Highlights solutions addressing key oncology research needs across automated sample preparation, single-cell analysis, genomic profiling and data analysisQIAsymphony Connect will serve as a...

Qiagen N : Sustainability Report (qiagen uk gender pay 2025 website v3)

2026-04-15
‌QIAGEN UK: 2025 Gender Pay Gap Report April 2026 ‌QIAGEN in the UK:...

Barclays Downgrades Qiagen N.V. (QGEN)

2026-04-15

Qiagen N.V. Expands into Bloodstream Infection Syndromic Testing with New Rapid QIAstat-Dx Panel

2026-04-14
QIAGEN N.V. had announced its expansion into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel. The launch of this new QIAstat-Dx...

QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel

2026-04-14
QIAstat-Dx BCID GPF Plus AMR Panel detects gram-positive bacteria, fungi and key antimicrobial resistance markers from positive blood cultures and coloniesCE-IVDR-certified panel identifies 20...

Barclays Downgrades Qiagen to Equal-Weight, Announces $44 Price Target

2026-04-14
Barclays analyst Luke Sergott downgrades Qiagen (NYSE:QGEN) from Overweight to Equal-Weight and announces $44 price target.

QIAGEN NV : Barclays is less optimistic

2026-04-14
Barclays changes its rating and switches from Buy to Neutral.

Qiagen (QGEN) Upgraded to Buy by Deutsche Bank After 30% Decline

2026-04-02
Qiagen N.V. (NYSE:QGEN) ranks among the oversold European stocks to buy. On March 13, Deutsche Bank upgraded Qiagen N.V. (NYSE:QGEN) to Buy from Hold, maintaining a $54 price target on the company’s shares. The firm stated that Qiagen’s stock had declined over 30% since late January’s M&A stories and accompanying downgrade, essentially pricing out any […]

Bruker Announces Appointment of Thierry Bernard to its Board of Directors

2026-04-01
BILLERICA, Mass., April 01, 2026--Bruker Corporation (Nasdaq: BRKR) announces the appointment of Mr. Thierry L. Bernard to serve on its Board of Directors, effective as of today. Mr. Bernard is an international life-science tools and diagnostics industry executive with decades of relevant leadership, strategic and operational experience.

Parse Biosciences, a QIAGEN Company, Launches FFPE-compatible Barcoding Technology for Whole Transcriptome Single Cell Analysis

2026-03-31
SEATTLE, March 31, 2026--Parse Biosciences, a QIAGEN company and the leading provider of scalable and accessible single-cell sequencing solutions, today announced the commercial availability of Evercode™ Whole Transcriptome FFPE kits that are now shipping to customers.